Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM-XAN006
- Development stage
- Preclinical
- Lead developer
- Xantho Biotechnology Co., LTD
- Administration
- Topical
01
Overview
GM-XAN006 is a preclinical-stage botanical drug candidate being developed by Xantho Biotechnology for the treatment of burn wounds. As part of Xantho's specialized pipeline of botanical dermatology products, GM-XAN006 has demonstrated the ability to accelerate wound healing in preclinical rat models of burn injury. The drug is designed to offer a therapeutic option with a low side-effect profile, leveraging the company's expertise in botanical extracts for dermatological conditions. While the specific active ingredients and molecular targets of GM-XAN006 have not been publicly disclosed, its development follows the company's focus on research-oriented botanical drug discovery.
Beyond the preview
Go deeper on GM-XAN006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM-XAN006.